REDEFININGCHRONICILLNESSa global solution for metabolic syndrome

GLOBAL HEALTH PLATFORMDDM operate Diabetes.co.uk and provide digital health solutions to people with diabetes, obesity and chronic disease

• More than 36m visitors a year

• 250,000 people from 195 countries enrolled in DDM education last year

• Unrivalled engagement from health-goal focused patient journeys personalized through AI/machine learning

• Infinite lifecycle of engagement through peer-to-peer support; behavioral change support; change maintenance support

the world’s biggest + most engaged community of PWD

DIGITAL EDUCATION

Scalable, engaging and effective digital-only tools to improve care and outcomes for people with, or at risk of, chronic disease.

▪ Evidence-based digital health interventions: AI-led, goal-focused, data-driven

▪ Creating sustainable behavioral change

▪ Integrated 24/7 social support

▪ Improve patient health outcomes

▪ Improve family health

▪ Reduce GP time burden

▪ Reduction in claims; increased cost savings

LOW CARB PROGRAM

Personalized, structured education programdeveloped with Dr Unwin and 20,000 people with T2D focused on therapeutic carbohydrate restriction

▪ Disease specific: Type 2 Diabetes, Prediabetes, Obesity

▪ Act: weekly Actions to encourage behavioural changes

▪ Resources: to support change and learned behaviours

▪ Track: HbA1c, mood, food intake, sleep, weight, blood glucose, waist-to-hip ratio, selfies, goals and more

▪ Support and maintenance: community-led Q&A system; AI-led infinite engagement lifecycle

▪ Available 24/7: desktop and native app (iOS/Android)

▪ Over 275,000 members

SUGAR VS CALORIES: THE EVIDENCE• 29 RCTs demonstrate that a low carb

approach is significantly more effective than low-calorie (low-fat) diets at 6 months, 1 year and 2 years

• Blood glucose normalization can be achieved by reducing sugar intake

• Type 2 Diabetes: not a chronic progressive disease

• Type 1 Diabetes: reduces long-term complications, improves management

DATA AND HEALTH INTELLIGENCE▪ Openness philosophy, not a privacy policy

▪ Patient owns their own data; consented for use to optimise patient journey

▪ World’s largest pool of real world patient data

▪ Data tracking

▪ Health goals; education; progression;

▪ Real-time: Weigh ins; activity data; blood glucose logging; food logging; mood; medication; selfie; epidemiolocal assessments;

▪ Wellbeing: Symptoms, illness progression, medication usage and other structured data

▪ Medication: Burden, perceived efficacy, adherence, side effects, sentiment

▪ Community

▪ Communication; interaction; ratings; sentiment (NLP)

▪ Engagement

▪ Demographic; geolocation data; usage

LOW CARB PROGRAM: OUTCOMES

LR Saslow, PhD, University of Michigan, Ann Arbor; JE Aikens, PhD, University of Michigan, Ann Arbor, DJ Unwin, FRCGP, Principal in General Practice, Southport, UK. Pending publication Q1 2018.

1,000 people at 1-year follow up; cost saving ~£830PPPY

REDUCING HBA1C BY 1% / 12 MMOL/MOL

Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes. British Medical Journal 2000; 321: 405-412Impact of Glycemic Control on Healthcare Resource Utilization and Costs of Type 2 Diabetes: American Health & Drug Benefits. 2013; 6(7): 382-392

REDUCES RISK OF DIABETES COMPLICATIONS

21% reduction in risk of any adverse outcome37% reduction in risk of microvascular complications

3.6%TOTAL HEALTHCARE COST

5.8%DIABETES RELATED COST

$256 $131

Impact of Glycemic Control on Healthcare Resource Utilization and Costs of Type 2 Diabetes: American Health & Drug Benefits. 2013; 6(7): 382-392

7% average weight loss for patients who complete the Low Carb Program

REDUCING WEIGHT BY 1%SIGNIFICANTLY REDUCES TOTAL HEALTHCARE COSTS

Basic Copyright Notice & Disclaimer

©2017 This presentation is copyright protected. All rights reserved. You may download or print out a hard copy for your private or internal use. You are not permitted to create any modifications or derivatives of this presentation without the prior written permission of the copyright owner.

This presentation is for information purposes only and contains non-binding indications. Any opinions or views expressed are of the author and do not necessarily represent those of Swiss Re. Swiss Re makes no warranties or representations as to the accuracy, comprehensiveness, timeliness or suitability of this presentation for a particular purpose. Anyone shall at its own risk interpret and employ this presentation without relying on it in isolation. In no event will Swiss Re be liable for any loss or damages of any kind, including any direct, indirect or consequential damages, arising out of or in connection with the use of this presentation.